The A/G allele of Rs16906252 predicts for MGMT methylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinomas

Clinical Cancer Research

Volumn 17, Issue 7, 2011, Pages 2014-2023

  Leng, Shuguang ^a   Bernauer, Amanda M ^a   Hong, Chibo ^d   Do, Kieu C ^a   Yingling, Christin M ^a   Flores, Kristina G ^b   Tessema, Mathewos ^a   Tellez, Carmen S ^a   Willink, Randall P ^a   Burki, Elizabeth A ^a   Picchi, Maria A ^a   Stidley, Christine A ^b   Prados, Michael D ^d   Costello, Joseph F ^d   Gilliland, Frank D ^e   Crowell, Richard E ^c   Belinsky, Steven A ^a  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; COMPLEMENTARY DNA; GUANINE; TEMOZOLOMIDE;

ADULT; AGED; ALLELE; ARTICLE; CANCER CELL; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG MECHANISM; ENHANCER REGION; EPITHELIUM CELL; GENE; GENE CONTROL; GENE EXPRESSION; GENE SEQUENCE; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HAPLOTYPE; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG ALVEOLUS EPITHELIUM; MAJOR CLINICAL STUDY; MGMT GENE; PRECANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; SINGLE NUCLEOTIDE POLYMORPHISM; SPUTUM;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BETA-GALACTOSIDASE; CELL LINE, TUMOR; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; LUCIFERASES; LUNG NEOPLASMS; MALE; METHYLATION; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECANCEROUS CONDITIONS; PROMOTER REGIONS, GENETIC; SMOKING; SPUTUM; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 79953323280     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3026     Document Type: Article

References (47)

1. Belinsky SA. Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 2005;26:1481-7. (Pubitemid 41236040)
2. Belinsky SA, Klinge DM, Liechty KC, March TH, Kang T, Gilliland FD, et al. Plutonium targets the p16 gene for inactivation by promoter hypermethylation in human lung adenocarcinoma. Carcinogenesis 2004;25:1063-7. (Pubitemid 38886088)
3. Cuozzo C, Porcellini A, Angrisano T, Morano A, Lee B, Di Pardo A, et al. DNA damage, homology-directed repair, and DNA methylation. PLoS Genet 2007;3:e110.
4. O'Hagan HM, Mohammad HP, Baylin SB. Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet 2008;4:e1000155.
5. Leng S, Stidley C, Willink R, Bernauer A, Do K, Picchi MA, et al. Double-strand break damage and associated DNA repair genes predispose smokers to gene methylation. Cancer Res 2008;68:3049-56. (Pubitemid 351556307)
6. Stidley CA, Picchi MA, Leng S, Willink R, Crowell RE, Flores KG, et al. Multivitamins, folate, and green vegetables protect against gene promoter methylation in the aerodigestive tract of smokers. Cancer Res 2010;70:568-74.
7. McCabe MT, Lee EK, Vertino PM. A multifactorial signature of DNA sequence and polycomb binding predicts aberrant CpG island methylation. Cancer Res 2009;69:282-91.
8. Feltus FA, Lee EK, Costello JF, Plass C, Vertino PM. Predicting aberrant CpG island methylation. Proc Natl Acad Sci U S A 2003;100:12253-8. (Pubitemid 37271547)
9. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, et al. Control of developmental regulators by polycomb in human embryonic stem cells. Cell 2006;125:301-13. (Pubitemid 44313811)
10. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, et al. Epigenetic stem cell signature in cancer. Nat Genet 2007;39:157-8. (Pubitemid 46184343)
11. Boumber YA, Kondo Y, Chen X, Shen L, Guo Y, Tellez C, et al. An Sp1/Sp3 binding polymorphism confers methylation protection. PLoS Genet 2008;4:e1000162.
12. Kerkel K, Spadola A, Yuan E, Kosek J, Jiang L, Hod E, et al. Genomic surveys by methylation-sensitive SNP analysis identify sequence-dependent allele-specific DNA methylation. Nat Genet 2008;40:904-8.
13. Zhang Y, Rohde C, Reinhardt R, Voelcker-Rehage C, Jeltsch A. Non-imprinted allele-specific DNA methylation on human autosomes. Genome Biol 2009;10:R138.
14. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008; 26:4189-99.
15. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-7. (Pubitemid 29086728)
16. Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Watkins DN, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000;60:2368-71. (Pubitemid 30262424)
17. Yin D, Xie D, Hofmann WK, Zhang W, Asotra K, Wong R, et al. DNA repair gene O6-methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors. Mol Carcinog 2003;36:23-31. (Pubitemid 36055812)
18. Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J, Vu K, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006;66:3338-44.
19. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 2010;6:39-51.
20. Harris LC, Remack JS, Brent TP. Identification of a 59 bp enhancer located at the first exon/intron boundary of the human O6-methylguanine DNA methyltransferase gene. Nucleic Acids Res 1994;22:4614-9. (Pubitemid 24354791)
21. Ogino S, Hazra A, Tranah GJ, Kirkner GJ, Kawasaki T, Nosho K, et al. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. Carcinogenesis 2007;28:1985-90. (Pubitemid 47514483)
22. Hawkins NJ, Lee JH, Wong JJ, Kwok CT, Ward RL, Hitchins MP. MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa. Mod Pathol 2009;22:1588-99.
23. Tessema M, Willink R, Do K, Yu YY, Yu W, Machida EO, et al. Promoter methylation of genes in and around the candidate lung cancer susceptibility locus 6q23-25. Cancer Res 2008;68:1707-14. (Pubitemid 351416555)
24. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res 2008;68:8535-40.
25. Tessema M, Yu YY, Stidley CA, Machida EO, Schuebel KE, Baylin SB, et al. Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers. Carcinogenesis 2009;30:1132-8.
26. Nakagawachi T, Soejima H, Urano T, Zhao W, Higashimoto K, Satoh Y, et al. Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene 2003;22:8835-44. (Pubitemid 38021499)
27. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89. (Pubitemid 32289743)
28. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162-9. (Pubitemid 37414228)
29. Stram DO, Haiman CA, Hirschhorn JN, Altshuler D, Kolonel LN, Henderson BE, et al. Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 2003;55:27-36. (Pubitemid 36928743)
30. Menashe I, Rosenberg PS, Chen BE. PGA: power calculator for case-control genetic association analyses. BMC Genet 2008;9:36.
31. Egyházi S, Ma S, Smoczynski K, Hansson J, Platz A, Ringborg U. Novel O6-methylguanine-DNA methyltransferase SNPs: a frequency comparison of patients with familial melanoma and healthy individuals in Sweden. Hum Mutat 2002;20:408-9.
32. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004;4:707-17. (Pubitemid 39215069)
33. Krześniak M, Butkiewicz D, Samojedny A, Chorazy M, Rusin M. Polymorphisms in TDG and MGMT genes - epidemiological and functional study in lung cancer patients from Poland. Ann Hum Genet 2004;68:300-12. (Pubitemid 39162742)
34. Wu H, Zhang X, Ling G, D'Agostino J, Ding X. Mechanisms of differential expression of the CYP2A13 7520C and 7520G alleles in human lung: allelic expression analysis for CYP2A13 heterogeneous nuclear RNA, and evidence for the involvement of multiple Cis-regulatory single nucleotide polymorphisms. Pharmacogenet Genomics 2009;19:852-63.
35. Cross SH, Bird AP. CpG islands and genes. Curr Opin Genet Dev 1995;5:309-14.
36. Pulling LC, Divine KK, Klinge DM, Gilliland FD, Kang T, Schwartz AG, et al. Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression. Cancer Res 2003;63:4842-8. (Pubitemid 37022615)
37. Zawlik I, Vaccarella S, Kita D, Mittelbronn M, Franceschi S, Ohgaki H. Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study. Neuroepidemiology 2009;32:21-9.
38. Rønneberg JA, Tost J, Solvang HK, Alnaes GI, Johansen FE, Brendeford EM, et al. GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas. Cancer Res 2008;68:5562-71.
39. Chan TL, Yuen ST, Kong CK, Chan YW, Chan AS, Ng WF, et al. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat Genet 2006;38:1178-83. (Pubitemid 44470364)
40. Candiloro IL, Dobrovic A. Detection of MGMT promoter methylation in normal individuals is strongly associated with the T allele of the rs16906252 MGMT promoter single nucleotide polymorphism. Cancer Prev Res (Phila Pa) 2009;2:862-7.
41. Song JZ, Stirzaker C, Harrison J, Melki JR, Clark SJ. Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene 2002;21:1048-61. (Pubitemid 34174517)
42. Stirzaker C, Song JZ, Davidson B, Clark SJ. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res 2004;64:3871-7. (Pubitemid 38697298)
43. Via M, Gignoux C, Burchard EG. The 1000 Genomes Project: new opportunities for research and social challenges. Genome Med 2010;2:3.
44. Rudin CM, Avila-Tang E, Harris CC, Herman JG, Hirsch FR, Pao W, et al. Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res 2009;15:5646-61.
45. Wolf J. Nitrosoureas as single agents in the treatment of pulmonary cancer. Cancer Treat Rep 1976;60:753-6.
46. Ahmann DL, Carr DT, Coles DT, Hahn RG. Evaluation of cyclophosphamide (NSC-26271) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in the treatment of patients with inoperable or disseminated lung cancer. Cancer Chemother Rep 1972;56:401-3.
47. Siena S, Crinò L, Danova M, Del Prete S, Cascinu S, Salvagni S, et al. Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Ann Oncol 2010;21:655-61.